Business
Results for the year ended 31 March 2025
Results for the year ended 31 March 2025.
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n14 July 2025\n\nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nResults for the year ended 31 March 2025\n \nECO Animal Health (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces its audited results for the year ended 31 March 2025.\n \nHIGHLIGHTS\n \nFinancial\n \n· Revenue in-line and adjusted EBITDA in-line with revised market expectations following strong second half to the year\n· Group sales of £79.6m (2024: £89.4m)\no North America revenue growth of 16%, contributing a growing share of Group revenues\n· Constant currency revenue £81.6m (2024: £89.4m)\n· Gross margin increased to 45% (2024: 42%), due to disciplined cost control and pricing, and geographical mix favouring high margin markets\n· Adjusted EBITDA of £7.3m (2024: £8.0m), in line with consensus\n· Adjusted EBITDA margin improved to 9.2% (2024: 9.0%)\n· Research and development expenditure increased to £8.6m (2024: £8.3m), as planned\n· Profit before tax increased to £4.0m (2024: £3.0m), driven in part by disposals of non-core assets\n· Earnings per share increased by 61% to 2.49p (2024: 1.55p)\n· Net cash at the end of the period £25.0m (2024: £22.4m), reinforcing the Group's strong balance sheet with 40% of cash held outside China (2024: 36%)\n· RCF facility (£10m) and overdraft (£5m) available and undrawn\n \nOperational\n \n· Aivlosin® demand continues to be robust in key markets, with particular growth in North America\n· Regulatory dossier for mycoplasma poultry vaccine ECOVAXXIN® MS submitted to EMA, with further submissions expected in next 12 months\n· Broader progress across R&D pipeline, with up to 9 products expected to receive US and EU approval in the next 5 - 6 years\n \n Post-year end highlights\n· Revenue in USA and China out performing budgets\n· Gross margins strengthening\n· South East Asia strong recovery with order book supporting outlook\n· C...